ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,429Medicare Part D Prescriptions Filled, Including Refills

Rank: 181 out of 890

$531K Total Retail Price of All Prescriptions

Rank: 227 out of 890

333 Patients Receiving at Least One Drug in Part D
74%Patients 65 Years and Older
72% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Louisiana
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

16% of this provider’s 333 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

3% of this provider’s 8,526 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$46 was the average price of a prescription from this provider, compared to $55 among peers.

Prescriptions per Patient

34 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Louisiana
HYDROCHLOROTHIAZIDE 588 439 1 9
LISINOPRIL 478 303 2 4
PRAVASTATIN SODIUM 423 301 3 10
SIMVASTATIN 360 261 4 5
AMLODIPINE BESYLATE 322 255 5 1
TRAMADOL HCL 322 250 5 16
OMEPRAZOLE 289 239 7 8
FUROSEMIDE 287 224 8 7
GLIMEPIRIDE 254 232 9 27
LEVOTHYROXINE SODIUM 248 191 10 2
METFORMIN HCL 240 163 11 6
ALENDRONATE SODIUM 237 209 12 38
ENALAPRIL MALEATE 224 179 13 56
CITALOPRAM HBR 181 136 14 20
ATENOLOL 180 137 15 23
NEXIUM 174 120 16 14
HYDROCODONE-ACETAMINOPHEN 151 122 S3 17 3
MELOXICAM 142 105 18 18
POTASSIUM CHLORIDE 141 99 19 11
AZITHROMYCIN 138 98 20 37
CRESTOR 133 61 21 25
GABAPENTIN 133 98 21 12
JANUVIA 125 114 23 59
ATORVASTATIN CALCIUM 120 111 24 13
PROAIR HFA 119 73 25 55
METOPROLOL SUCCINATE 117 107 26 17
SERTRALINE HCL 114 90 27 26
CYMBALTA 107 71 28 45
GLYBURIDE 106 83 R 29 83
METOPROLOL TARTRATE 97 83 30 15
INDAPAMIDE 93 82 31 148
KLOR-CON M20 93 71 31 72
DIOVAN 91 59 33 33
BUSPIRONE HCL 89 49 34 133
AMITRIPTYLINE HCL 87 57 R 35 43
LOVASTATIN 86 73 36 46
TRAZODONE HCL 83 51 37 40
ZOLPIDEM TARTRATE 83 79 37 19
FLUTICASONE PROPIONATE 83 58 37 39
LANTUS 82 77 40 50
DONEPEZIL HCL 76 64 41 30
LOSARTAN POTASSIUM 70 55 42 29
RANITIDINE HCL 63 53 43 49
PREDNISONE 63 42 43 47
TRICOR 63 49 43 98
ALLOPURINOL 60 47 46 31
LIPITOR 59 57 47 77
LYRICA 59 41 47 71
CYCLOBENZAPRINE HCL 59 27 R 47 64
TRIAMTERENE-HCTZ 58 55 50 61
VERAPAMIL ER 55 30 51 87
WARFARIN SODIUM 53 49 52 24
CIPROFLOXACIN HCL 52 40 53 58
DETROL LA 51 45 54 164
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 18, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.